Trial of latest weight-loss drug propels Novo Nordisk stock market value to €517bn

Phase I trial of the pill version of experimental drug amycretin showed participants lost over 13% of their weight. That compares to a weight loss of about 6% in trials for Wegovy, its blockbuster obesity drug

The Wegovy weight-loss drug had already boosted Novo Nordisk before trials of a new drug.

Shares in Denmark's Novo Nordisk soared more than 8% after early trial data for its experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment.  

Novo Nordisk shares surpassed Tesla in market valuation after the maker of the popular weight-loss drug Wegovy announced positive early trial data for a highly-anticipated new obesity drug.